- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01123187
Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation
Phase 2 Study of Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation With Steroid Free Immunosuppression
Study Overview
Status
Intervention / Treatment
Detailed Description
The beneficial effects of glycemic control on both survival and function of transplanted kidneys in patients with type 1 diabetes mellitus have been recognized.
The purpose of this study is to reverse hyperglycemia and insulin dependency, by islet cell transplantation, in patients with type 1 diabetes mellitus who have a stable kidney allograft.
The study primary efficacy endpoint is graft survival defined as insulin independence and HbA1c < 8% at 1 year post first transplant. Secondary outcomes are graft function and metabolic control
The immunosuppression protocol for the kidney graft was converted to sirolimus+tacrolimus regimen 6 months before islet transplantation to exclude negative effects on kidney graft function.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nord
-
Lille, Nord, France, 59000
- University Hospital of Lille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 1 diabetes mellitus. Documentation of negative basal and stimulated C-peptide and diagnosis of diabetes for at least 5 years.
- Recipient of renal transplant with good function (creatinine clearance >/=60 ml/min)
- Stable immunosuppression consisting of any combination of sirolimus, tacrolimus for at least 6 months, without major complications
- Ability to give informed consent.
- Age greater than or equal to 18 years or less than or equal to 65 years
- No evidence of liver disease (liver enzymes < twice the upper limit of normal)
Exclusion Criteria:
- Age below 18 years and above 65 years
- Significant cardiovascular disease, including non-correctable coronary artery disease and/or recent myocardial infarction(within last 12 months); extensive peripheral vascular disease not correctable by surgery, unstable angina
- Untreated proliferative retinopathy.
- Recent Cerebrovascular accident (within last 12 months)
- Recent unresolved acute infection, or chronic infection, including tuberculosis, HIV, HBV, HCV, CMV or positive skin test for TB
- Any history of malignancy, except squamous or basal skin cancer or in situ cancer of the cervix.
- History of non-compliance, or inability to demonstrate capacity to comply with strict blood glycemic control and insulin pump therapy.
- Psychiatric illness that is untreated, or likely to interfere significantly with transplantation despite treatment.
- Pregnant women, women intending future pregnancy, women of reproductive potential who are unable or unwilling to follow effective contraceptive measures for the duration of immunosuppressive therapy
- Fasting C-peptide > 0.2 ng/ml
- Creatinine > 25mg/l
- Alkaline phosphatase, total bilirubin, Alanine Aminotransferase (ALT)or Aspartate Aminotransferase (AST) > twice the upper limit of normal
- Significant liver disease (elevation of liver enzymes > twice the upper limit of normal for each of ALT and AST, liver masses including portal vein thrombosis, evidence of portal hypertension, or significant, untreated gallbladder disease (i.e., gallstones).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: islet transplantation
Islet transplantation
|
Islet transplantation consisted of up to three sequential fresh islet infusions within three months.
Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite criteria: insulin independence and Glycosylated Hemoglobin (HbA1c) under 8% at one year after the transplantation
Time Frame: One year
|
Percent of insulin-independent patients with a Glycosylated Hemoglobin (HbA1c) under 8% at one year after injection of approximately 10,000 islets equivalents / kg (IE/kg).
|
One year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of adverse events
Time Frame: 1 year
|
The number of adverse events related to the procedure and to the immunosuppression
|
1 year
|
Number of severe episodes of hypoglycemia
Time Frame: 1 year
|
Number of severe episodes of hypoglycemia (requiring the use of third)
|
1 year
|
Evaluation of Diabetes complications
Time Frame: 1 year
|
Evaluation of Diabetes complications: retinopathy, neuropathy, nephropathy
|
1 year
|
Lipid metabolism
Time Frame: 1 year
|
Lipid metabolism assessed by measurement of total cholesterol and HDL cholesterol, triglycerides, ApoA1, apoB, apoE, free fatty acids and lipid.
|
1 year
|
Evaluation of kidney function
Time Frame: 1 year
|
Evaluation of kidney function (creatinine, creatinine clearance,proteinurie)
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marie-Christine VANTYGHEM, MD, University Hospital, Lille
- Principal Investigator: Christian NOEL, MD, University Hospital, Lille
- Principal Investigator: Julie KERR-CONTE, MD, Université de Lille 2
Publications and helpful links
General Publications
- Vantyghem MC, Chetboun M, Gmyr V, Jannin A, Espiard S, Le Mapihan K, Raverdy V, Delalleau N, Machuron F, Hubert T, Frimat M, Van Belle E, Hazzan M, Pigny P, Noel C, Caiazzo R, Kerr-Conte J, Pattou F; Members of the Spanish Back Pain Research Network Task Force for the Improvement of Inter-Disciplinary Management of Spinal Metastasis. Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study. Diabetes Care. 2019 Nov;42(11):2042-2049. doi: 10.2337/dc19-0401. Erratum In: Diabetes Care. 2020 May;43(5):1164.
- Benomar K, Chetboun M, Espiard S, Jannin A, Le Mapihan K, Gmyr V, Caiazzo R, Torres F, Raverdy V, Bonner C, D'Herbomez M, Pigny P, Noel C, Kerr-Conte J, Pattou F, Vantyghem MC. Purity of islet preparations and 5-year metabolic outcome of allogenic islet transplantation. Am J Transplant. 2018 Apr;18(4):945-951. doi: 10.1111/ajt.14514. Epub 2017 Nov 11.
- Caiazzo R, Vantyghem MC, Raverdi V, Bonner C, Gmyr V, Defrance F, Leroy C, Sergent G, Hubert T, Ernst O, Noel C, Kerr-Conte J, Pattou F. Impact of Procedure-Related Complications on Long-term Islet Transplantation Outcome. Transplantation. 2015 May;99(5):979-84. doi: 10.1097/TP.0000000000000458.
- Vantyghem MC, Raverdy V, Balavoine AS, Defrance F, Caiazzo R, Arnalsteen L, Gmyr V, Hazzan M, Noel C, Kerr-Conte J, Pattou F. Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (beta-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (beta-score greater than 3). J Clin Endocrinol Metab. 2012 Nov;97(11):E2078-83. doi: 10.1210/jc.2012-2115. Epub 2012 Sep 20.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP 95/120
- 98001 (OTHER: Sponsor)
- DGS 980032 (OTHER: AFSSAPS)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on islet transplantation
-
University Hospital, LilleCompletedIslet TransplantationFrance
-
Rodolfo AlejandroNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedDiabetes Mellitus, Type 1United States
-
The Nordic Network For Clinical Islet TransplantationUnknownType 1 Diabetes | End Stage Renal Disease
-
Rodolfo AlejandroJuvenile Diabetes Research Foundation; Diabetes Research Institute FoundationActive, not recruitingHypoglycemia | Type 1 Diabetes Mellitus | Hypoglycemia UnawarenessUnited States
-
National Institute of Diabetes and Digestive and...Completed
-
Frantisek SaudekRecruitingIslets of Langerhans TransplantationCzechia
-
Weill Medical College of Cornell UniversityTerminated
-
National Center for Research Resources (NCRR)UnknownDiabetes Mellitus
-
National Institute of Diabetes and Digestive and...CompletedDiabetes Mellitus, Type 1United States
-
Baylor Research InstituteUniversity of Miami; Baylor Health Care SystemCompleted